Patient P-03001
Therapy response
Improving
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Favorable
Discontinuation risk
27%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S04
- Day 26 CR-01 recommended — Clinician Review CR-01
- Day 27 Patient accepted — Started CR-01 in the companion
- Day 32 Deterioration detected before clinical escalation — Clinician Review CR-01
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- GI instability+14
- Toxicity+10
- Treatment adherence-7
- Inflammatory activity+5
- Nutritional resilience-4
What helped?
- Clinician Review CR-01Day 26Result: deterioration detected before clinical escalation
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log6.9/10
worsening · -0.3 vs previous 14 d
Stress level
Daily log3.5/10
stable · +0.0 vs previous 14 d
Pessimism score
Daily log2.4/10
improving · -0.2 vs previous 14 d
Sleep quality
Wearable36.3/100
worsening · -5.1 vs previous 14 d
Libido
Daily log5.6/10
stable · -0.1 vs previous 14 d
HRV
Wearable63.9 ms
stable · -1.3 vs previous 14 d
Toxicity
Blood12.6/100
worsening · +4.2 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 96 from the failing basin, 10 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -5.5 next day on high-intake days · n 17
Would not help
- Nothing clearly counter-productive in the record.
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-5.5supporter · 95%
- Lactose-1.7no signal · 35%
- Dietary fat load+1.5no signal · 40%
- Alcohol-0.5no signal · 15%
- Histamine load-0.2no signal · 15%
- Caffeine-0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Autonomic recovery ↓40
- Wearable3,885 steps/day
- WearableShort sleep window
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
- Mucosal barrier integrity ↓10
- WearableSleep 5.1 h, below personal baseline
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.4 · butyrate capacity 66/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 67 ms
- Sleep
- 5.8 h
- Steps
- 5,192
- Resting HR
- 66 bpm
Daily log: GI score 15, nutritional resilience 69, adherence 91.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03431 | 52% | S05 | DT-01 | improved | 88 |
| P-03018 | 49% | S05 | ME-01 | improved | 84 |
| P-03140 | 49% | S20 | AD-05 | improved | 79 |
| P-03165 | 47% | S06 | NP-02 | improved | 79 |
| P-03288 | 45% | S15 | CR-01 | improved | 88 |
| P-03008 | 42% | S16 | SC-12 | improved | 87 |
| P-03449 | 36% | S14 | DT-01 | improved | 79 |
| P-03333 | 34% | S14 | SC-12 | improved | 91 |
| P-03473 | 32% | S07 | DT-01 | improved | 70 |
| P-03188 | 31% | S13 | HY-01 | improved | 79 |
| P-03208 | 29% | S02 | BR-03 | improved | 57 |
| P-03252 | 29% | S13 | SC-12 | improved | 68 |